This page lists the SEC filings reported by CHI Advisors LLC.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2023-02-13 | CHI Advisors LLC | Cullinan Oncology, Inc. | 3,317,544 | 7.2% | EDGAR |
| SC 13G/A | 2023-02-13 | CHI Advisors LLC | Freeline Therapeutics Holdings plc | 4,814,419 | 7.4% | EDGAR |
| SC 13G/A | 2023-02-13 | CHI Advisors LLC | Larimar Therapeutics, Inc. | 3,473,366 | 8.0% | EDGAR |
| SC 13G/A | 2023-02-13 | CHI Advisors LLC | Oncorus, Inc. | 2,367,436 | 9.1% | EDGAR |
| SC 13G/A | 2023-02-13 | CHI Advisors LLC | Orchard Therapeutics plc | 7,987,396 | 6.3% | EDGAR |
| SC 13G/A | 2023-02-13 | CHI Advisors LLC | PLIANT THERAPEUTICS, INC. | 3,199,892 | 6.6% | EDGAR |
| SC 13G/A | 2023-02-13 | CHI Advisors LLC | Repare Therapeutics Inc. | 2,800,126 | 6.7% | EDGAR |
| SC 13G/A | 2023-02-13 | CHI Advisors LLC | VectivBio Holding AG | 5,492,893 | 8.8% | EDGAR |
| SC 13G | 2023-02-13 | CHI Advisors LLC | Corvus Pharmaceuticals, Inc. | 2,384,402 | 5.1% | EDGAR |
| SC 13G | 2023-02-13 | CHI Advisors LLC | Inozyme Pharma, Inc. | 2,204,876 | 5.5% | EDGAR |
| SC 13G/A | 2022-02-11 | CHI Advisors LLC | Larimar Therapeutics, Inc. | 1,515,148 | 8.6% | EDGAR |
| SC 13G/A | 2022-02-11 | CHI Advisors LLC | Oncorus, Inc. | 2,106,903 | 8.2% | EDGAR |
| SC 13G/A | 2022-02-11 | CHI Advisors LLC | PLIANT THERAPEUTICS, INC. | 2,569,479 | 7.1% | EDGAR |
| SC 13G/A | 2022-02-11 | CHI Advisors LLC | Repare Therapeutics Inc. | 2,212,256 | 5.3% | EDGAR |
| SC 13G | 2022-02-11 | CHI Advisors LLC | Cullinan Oncology, Inc. | 2,476,720 | 5.7% | EDGAR |
| SC 13G | 2022-02-11 | CHI Advisors LLC | VectivBio Holding AG | 2,675,408 | 7.6% | EDGAR |
| SC 13G | 2022-02-11 | CHI Advisors LLC | Freeline Therapeutics Holdings plc | 1,876,389 | 5.2% | EDGAR |
| SC 13G | 2022-02-11 | CHI Advisors LLC | Orchard Therapeutics plc | 6,449,856 | 5.1% | EDGAR |
| SC 13G | 2021-03-02 | CHI Advisors LLC | Oncorus, Inc. | 1,679,906 | 6.6% | EDGAR |
| SC 13G | 2021-03-02 | CHI Advisors LLC | Larimar Therapeutics, Inc. | 1,515,148 | 9.9% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.